Averin Capital Acquisition, a blank check company backed by Averin Capital, has successfully priced its $250 million initial public offering, marking another sign of renewed momentum in the SPAC market. The company offered 25 million units at $10 per unit, with each unit comprising one share of common stock and one-sixth of a warrant exercisable at $11.50.

The New York-based special purpose acquisition company plans to list on the Nasdaq under the ticker symbol ACAAU.

Leadership Anchored by Veteran Health-Tech Builder

The SPAC is led by Chairman and CEO David Berry, who co-founded Averin Capital in 2023, formerly known as Bedford Bridge. Berry previously served as a General Partner at Flagship Pioneering, where he played a key role in launching and building more than 30 companies. Among them was Valo Health, which he co-founded and led as CEO.

Berry currently serves as Chairman of Osler Diagnostics and sits on the boards of Oaktree Acquisition III Life Sciences, Hologen, Biolinq, and Salma Health. His experience spans company formation, biotech innovation, and scaling emerging health platforms.

He is joined by CFO Alex Lau, who has been Partner and Head of Operations at Averin Capital since February 2025. Together, the leadership team brings operational depth and sector expertise aimed at identifying high-growth opportunities.

Strategic Focus on Technology-Driven Health Transformation

Averin Capital Acquisition intends to target businesses operating at the intersection of healthcare and technology. The company believes the health economy is undergoing structural transformation, creating opportunities for disruptive innovators to challenge legacy incumbents.

Management highlights advancements in artificial intelligence, automation, and digital infrastructure as key catalysts reshaping healthcare delivery, diagnostics, and therapeutics. The SPAC aims to partner with companies leveraging these technologies to modernize and scale healthcare platforms globally.

Market Context and Underwriting Support

Deutsche Bank acted as sole bookrunner on the transaction. The deal marks Deutsche Bank’s second SPAC IPO of the year following a hiatus of more than three years, signaling that major investment banks are gradually re-entering the SPAC underwriting space after a prolonged slowdown.

The successful pricing reflects improving investor appetite for well-positioned SPAC sponsors, particularly those with strong sector track records and clearly defined acquisition strategies.

Outlook

With $250 million in fresh capital and leadership experienced in building health innovation platforms, Averin Capital Acquisition enters the public markets positioned to pursue transformative deals in health and technology.

The next critical phase will involve identifying a compelling target capable of capturing value in a rapidly evolving healthcare ecosystem increasingly driven by AI, automation, and digital transformation.

Confidential Advisory: This article is for informational purposes only and does not constitute investment advice. Readers should conduct independent due diligence before making any investment decisions